Clinical Trial Update: High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating high-dose furmonertinib alone or in combination with chemotherapy in EGFR-mutant advanced non-small cell lung cancer after p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)

Snippet

Sponsor: Jialei Wang | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: RECRUITING